Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $1.81 Million in Progyny, Inc. $PGNY

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Progyny, Inc. (NASDAQ:PGNY) in the 4th quarter, HoldingsChannel reports. The fund acquired 70,312 shares of the company’s stock, valued at approximately $1,806,000.

Several other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after acquiring an additional 235,513 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its position in shares of Progyny by 2.1% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,931,249 shares of the company’s stock valued at $41,560,000 after acquiring an additional 39,666 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its position in shares of Progyny by 10.7% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,834,104 shares of the company’s stock valued at $47,100,000 after acquiring an additional 177,546 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after acquiring an additional 696,447 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Down 3.7%

Shares of PGNY stock opened at $24.69 on Friday. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 32.06, a PEG ratio of 1.36 and a beta of 0.91. The business’s fifty day moving average is $18.92 and its 200 day moving average is $22.01. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $28.75.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.03. The company had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities research analysts expect that Progyny, Inc. will post 1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the sale, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Melissa B. Cummings sold 9,578 shares of the stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total value of $239,450.00. Following the sale, the chief operating officer directly owned 73,371 shares in the company, valued at $1,834,275. This trade represents a 11.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 25,308 shares of company stock valued at $579,977. 9.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

PGNY has been the subject of a number of research analyst reports. Canaccord Genuity Group upgraded Progyny from a “hold” rating to a “buy” rating and lifted their price target for the company from $19.00 to $30.00 in a research report on Tuesday. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating and issued a $30.00 target price on shares of Progyny in a research report on Friday, March 6th. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Finally, Truist Financial lifted their price target on Progyny from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.55.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.